系统性红斑狼疮患者血浆白细胞介素-17A的表达及临床意义

Expression and clinical significance of plasma interleukin-17A in systemic lupus erythematosus

目的:探讨白细胞介素-17A(IL-17A)在系统性红斑狼疮(SLE)患者血浆中的水平变化及其临床意义。方法:应用ELISA法检测初发SLE患者未用激素治疗组13例、激素治疗组47例及29名健康志愿者(对照组)血浆中IL-17A的水平,比较3组的差异并分析IL-17A水平与临床指标的关系。结果:未用激素治疗组IL-17A水平均高于对照组及激素治疗组(P<0.05和P<0.01)。IL-17A水平与红细胞沉降率和C4均呈负相关关系(P<0.05);而与C3、IgG、抗ds-DNA、SLE疾病活动性指数和24 h尿蛋白定量均无相关关系(P>0.05)。结论:未用激素治疗组血浆IL-17A的水平比对照组升高,IL-17A在SLE的发病中可能发挥着重要的作用,激素治疗可显著降低SLE患者IL-17A水平。

Objective：To investigate the changes of plasma interleukin-17A（IL-17A） level in patients with systemic lupus erythematosus（SLE） and analyze the clinical implication. Methods：Plasma IL-17A level was measured by ELISA from 60 SLE patients（13 without glucocorticoid treatment and 47 with glucocorticoid treatment） and 29 healthy persons.The relationship between IL-17A and clinical or laboratory parameters of SLE patients was explored. Results：IL-17A levels were elevated significantly in SLE patients without glucocorticoid treatment than in SLE patients with glucocorticoid treatment or healthy persons（P0.05-P0.01）.The negative correlation was observed between IL-17A expression and C4,erythrocyte sedimentation rate（P0.05）,but no correlation with C3,IgG,anti ds-DNA antibody,SLE disease activity index score and 24 h urine protein excretion（P0.05）. Conclusions：The level of plasma IL-17A in SLE patient without glucocorticoid treatment was higher than in normal control.IL-17A might play an important role in the pathogenesis of SLE.Treatment with glucocorticoid can decrease IL-17A level in SLE significantly.